HomeProductsLife ScienceAPIsAPIEnocitabine
Chemical structure of CAS 55726-47-1

Enocitabine

In Stock•Starting at $277 for 25 mg•Purity ≥ 98%
CAS No.55726-47-1
MDL No.N/A
MFC31H55N3O6
MW565.80
InChI KeySAMRUMKYXPVKPA-VFKOLLTISA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
25 mg98%$277In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Enocitabine is an organic molecule.

CAS No.55726-47-1
Product NameEnocitabine
Heavy Atom Count40Rotatable Bond Count23
Atom Stereo Count4Bond Stereo Count0
HBA8HBD4
TPSA133.910 ŲCharge0
Exact Mass565.40909Complexity863.72
pKa7.130XLogP5.615

Related Articles

Studies related to this compound and its mechanism of action

Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.

Journal of Korean medical science • Vol. 25, Issue 1 • 2010
PMID: 20052341PMC: PMC2800026DOI: 10.3346/jkms.2010.25.1.9

The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.

Journal of Korean medical science • Vol. 24, Issue 3 • 2009
PMID: 19543516PMC: PMC2698199DOI: 10.3346/jkms.2009.24.3.498

Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.

European journal of haematology • Vol. 79, Issue 5 • 2007
PMID: 17916082DOI: 10.1111/j.1600-0609.2007.00946.x

[Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].

[Rinsho ketsueki] The Japanese journal of clinical hematology • Vol. 46, Issue 3 • 2005
PMID: 16447716

Documentation

Similar Products